QUIDELORTHO CORP Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum
QUIDELORTHO CORP (QDEL) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum of 3.94% for the 12-month period ending 2025-12-28, per its 10-K filed 2026-02-19.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum · last filed 2026-02-19
- QUIDELORTHO CORP share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for the quarter ending 2023-04-02 was 3.63%, a 122.70% increase year-over-year.
- QUIDELORTHO CORP share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for the quarter ending 2022-04-03 was 1.63%.
- QUIDELORTHO CORP share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for fiscal 2025 was 3.94%, a 14.35% decline from fiscal 2024.
- QUIDELORTHO CORP share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for fiscal 2024 was 4.60%, a 30.68% increase from fiscal 2023.
- QUIDELORTHO CORP share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for fiscal 2023 was 3.52%, a 79.59% increase from fiscal 2023.
- QUIDELORTHO CORP share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for fiscal 2023 was 1.96%, a 308.33% increase from fiscal 2022.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum 12 month |
|---|---|---|---|---|---|
| 2025-12-28 | 3.94% 10-K · filed 2026-02-19 | ||||
| 2024-12-29 | 4.60% 10-K · filed 2026-02-19 | ||||
| 2023-12-31 | 3.52% 10-K · filed 2026-02-19 | ||||
| 2023-10-01 | 3.52% 10-Q · filed 2023-11-02 | ||||
| 2023-07-02 | 3.52% 10-Q · filed 2023-08-09 | ||||
| 2023-04-02 | 3.63% 10-Q · filed 2023-05-04 | ||||
| 2023-01-01 | 1.96% 10-K · filed 2025-02-27 | ||||
| 2022-10-02 | 1.99% 10-Q · filed 2023-11-02 | ||||
| 2022-07-03 | 1.99% 10-Q · filed 2023-08-09 | ||||
| 2022-05-27 | 2.28% 10-K · filed 2023-02-23 | ||||
| 2022-04-03 | 1.63% 10-Q · filed 2023-05-04 | ||||
| 2022-01-02 | 0.48% 10-K/A · filed 2024-08-01 | ||||
| 2021-10-03 | 0.48% 10-Q · filed 2022-11-04 | ||||
| 2021-07-04 | 0.42% 10-Q · filed 2022-08-05 | ||||
| 2021-01-03 | 1.18% 10-K · filed 2023-02-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |
| Cardio Diagnostics Holdings, Inc. (CDIO) | United States | $0.006B | |
| VOLITIONRX LTD (VNRX) | $0.003B | -0.64 | |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |